Brokerages Expect Bausch Health Companies Inc (BHC) Will Post Earnings of $0.89 Per Share

Equities analysts expect that Bausch Health Companies Inc (NYSE:BHC) will post $0.89 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Seven analysts have issued estimates for Bausch Health Companies’ earnings. The lowest EPS estimate is $0.78 and the highest is $0.97. Bausch Health Companies also posted earnings per share of $0.89 during the same quarter last year. The business is expected to report its next quarterly earnings report before the market opens on Monday, May 6th.

On average, analysts expect that Bausch Health Companies will report full-year earnings of $3.93 per share for the current financial year, with EPS estimates ranging from $3.64 to $4.28. For the next year, analysts forecast that the company will report earnings of $4.19 per share, with EPS estimates ranging from $3.53 to $4.77. Zacks Investment Research’s EPS averages are an average based on a survey of analysts that that provide coverage for Bausch Health Companies.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings data on Wednesday, February 20th. The company reported $1.05 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.84 by $0.21. The business had revenue of $2.12 billion for the quarter, compared to the consensus estimate of $2.08 billion. Bausch Health Companies had a positive return on equity of 39.91% and a negative net margin of 50.83%. The firm’s revenue was down 1.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.98 EPS.



Several research firms have issued reports on BHC. SunTrust Banks began coverage on Bausch Health Companies in a research note on Tuesday, March 19th. They issued a “buy” rating and a $30.00 price target on the stock. Bank of America restated an “underperform” rating and issued a $18.00 price objective on shares of Bausch Health Companies in a report on Wednesday, March 20th. Zacks Investment Research cut Bausch Health Companies from a “buy” rating to a “hold” rating in a report on Friday, February 15th. ValuEngine upgraded Bausch Health Companies from a “sell” rating to a “hold” rating in a report on Monday, February 4th. Finally, Wells Fargo & Co lifted their price target on Bausch Health Companies from $9.00 to $25.19 and gave the stock an “underperform” rating in a report on Tuesday, February 19th. Five analysts have rated the stock with a sell rating, four have given a hold rating and eleven have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $27.36.

In related news, CEO Joseph C. Papa acquired 30,000 shares of the business’s stock in a transaction on Thursday, February 28th. The stock was purchased at an average cost of $23.67 per share, for a total transaction of $710,100.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 11.87% of the company’s stock.

A number of hedge funds have recently modified their holdings of BHC. Vanguard Group Inc. acquired a new stake in shares of Bausch Health Companies in the third quarter valued at approximately $223,173,000. Vanguard Group Inc acquired a new position in Bausch Health Companies during the third quarter valued at approximately $223,173,000. Connor Clark & Lunn Investment Management Ltd. raised its position in Bausch Health Companies by 0.9% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 8,452,664 shares of the company’s stock valued at $156,267,000 after purchasing an additional 75,175 shares in the last quarter. Orbimed Advisors LLC raised its position in Bausch Health Companies by 89.1% during the fourth quarter. Orbimed Advisors LLC now owns 3,600,300 shares of the company’s stock valued at $66,498,000 after purchasing an additional 1,696,400 shares in the last quarter. Finally, AQR Capital Management LLC acquired a new position in Bausch Health Companies during the third quarter valued at approximately $84,485,000. Hedge funds and other institutional investors own 54.67% of the company’s stock.

BHC opened at $23.13 on Thursday. Bausch Health Companies has a 1 year low of $16.91 and a 1 year high of $28.45. The stock has a market capitalization of $8.09 billion, a price-to-earnings ratio of 5.75, a PEG ratio of 0.55 and a beta of 0.59. The company has a debt-to-equity ratio of 8.55, a quick ratio of 0.85 and a current ratio of 1.10.

Bausch Health Companies Company Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

See Also: Cost of Equity For A Business, Investors

Get a free copy of the Zacks research report on Bausch Health Companies (BHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.